Controlled-release solid dosage forms of mesalamine
Described are controlled-release solid dosage forms of mesalamine. In one aspect of the invention the controlled-release solid dosage forms of mesalamine are capsules comprising a plurality of coated mini-tablets. Another aspect of the invention relates to a method of treating a patient suffering from inflammatory bowel disease, comprising the step of administering to the patient a therapeutically effective amount of the solid dosage form. The invention also relates to methods of inducing remission of inflammatory bowel disease and maintaining remission of inflammatory bowel disease. In certain aspects, the inflammatory bowel disease is ulcerative colitis or Crohn's disease.
1. A controlled-release solid dosage form, comprising a plurality of mini-tablets, wherein each mini-tablet comprises:
(a) a core, comprising mesalamine; and
(b) a coating, comprising low-viscosity ethyl cellulose; and a pore-forming agent selected from the group consisting of hydroxypropyl cellulose and hydroxypropyl methylcellulose;
wherein the coating surrounds the core and the number of mini-tablets in the dosage form is about 30 to about 100.
2. The solid dosage form of claim 1 , wherein the core further comprises a diluent.
3. The solid dosage form of claim 1 , wherein the core further comprises a binder.
4. The solid dosage form of claim 1 , wherein the core further comprises a lubricant.
5. The solid dosage form of claim 1 , wherein the coating further comprises a plasticizer.
6. The solid dosage form of claim 1 , wherein the diameter of the mini-tablets is about 1 mm to about 5 mm.
7. The solid dosage form of claim 1 , wherein the viscosity of the low-viscosity ethyl cellulose is less than about 15 cP.
8. The solid dosage form of claim 1 , wherein the ratio in the coating of the low-viscosity ethyl cellulose to the pore-forming agent is about 7:3 to about 4:6.
9. The solid dosage form of claim 1 , wherein the viscosity of the hydroxypropyl cellulose or hydroxypropyl methylcellulose is about 3 cP to about 15 cP.
10. The solid dosage form of claim 1 , wherein the weight percentage of the mesalamine is about 75% to about 85% based on the weight of the core.
11. The solid dosage form of claim 1 , wherein the weight percentage of the mesalamine is about 40% to about 90% by weight of the mini-tablet.
12. The solid dosage form of claim 1 , wherein the solid dosage form is a capsule; and the capsule comprises the plurality of mini-tablets.
13. The solid dosage form of claim 1 , wherein the amount of mesalamine is about 200 mg to about 1,000 mg.
14. The solid dosage form of claim 1 , comprising
(a) a core, comprising mesalamine in about 80% by weight of the core; lactose in about 16% by weight of the core; hydroxypropyl cellulose in about 3% by weight of the core; and a lubricant in about 1% by weight of the core; and
(b) a coating, comprising low-viscosity ethyl cellulose; a pore-forming agent; and triethyl citrate;
wherein the coating surrounds the core; and the coating comprises from about 1% to about 6% by weight of the mini-tablet.
15. The solid dosage form of claim 1 , wherein the solid dosage form comprises about 500 mg of mesalamine; and oral administration of two of the solid dosage forms to a healthy adult human results in a C max of from about 300 ng/mL to about 7500 ng/mL.
16. The solid dosage form of claim 1 , wherein the solid dosage form comprises about 500 mg of mesalamine; and oral administration of two of the solid dosage forms to a healthy adult human results in a T max of from about 5 hours to about 8 hours.
17. The solid dosage form of claim 1 , wherein each mini-tablet further comprises an enteric coating.
18. A method of treating, inducing remission of, or maintaining remission of inflammatory bowel disease, comprising the step of orally administering to a mammal in need thereof a therapeutically effective amount of a solid dosage form of claim 1 .
19. The method of claim 18 , wherein the inflammatory bowel disease is ulcerative colitis or Crohn's disease.
20. The method of claim 18 , wherein the total daily dose of mesalamine is about 1 g to about 5 g.
21. The method of claim 18 , further comprising the step of coadministering to the mammal in need thereof a therapeutically effective amount of a steroid.